A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Barbara Eichhorst; Carsten Niemann; Arnon P. Kater; Moritz Fürstenau; Julia Von Tresckow; Can Zhang; Sandra Robrecht; Michael Gregor; Gunnar Juliusson; Patrick Thornton; Philipp B. Staber; Tamar Tadmor; Vesa Lindström; Caspar Da Cunha-Bang; Christof Schneider; Christian Bjørn Poulsen; Thomas Illmer; Björn Schöttker; Ann Janssens; Ilse Christiansen; Thomas Noesslinger; Michael Baumann; Marjolein van der Klift; Ulrich Jaeger; Henrik Frederiksen; Maria B.L. Leijs; Mels Hoogendoorn; Kourosh Lotfi; Holger Hebart; Tobias Gaska; Harry R. Koene; Florian Simon; Nisha De Silva; Anna-Maria Fink; Kirsten Fischer; Clemens-Martin Wendtner; Karl-Anton Kreuzer; Matthias Ritgen; Monika Brüggemann; Eugen Tausch; Mark-David Levin; Marinus H.J. Van Oers; Christian H. Geisler; Stephan Stilgenbauer; Michael Hallek

doi:10.1182/blood-2021-146161

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Barbara Eichhorst, Carsten Niemann, Arnon P. Kater, Moritz Fürstenau, Julia Von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar Da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse ChristiansenThomas Noesslinger, Michael Baumann, Marjolein van der Klift, Ulrich Jaeger, Henrik Frederiksen, Maria B.L. Leijs, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry R. Koene, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark-David Levin, Marinus H.J. Van Oers, Christian H. Geisler, Stephan Stilgenbauer, Michael Hallek

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Article number	71
Journal	Blood
Volume	138
Issue number	Suppl. 1
Number of pages	1
ISSN	0006-4971
DOIs	https://doi.org/10.1182/blood-2021-146161
Publication status	Published - 1 Nov 2021
Event	Ash Annual Meeting & Exposition - Georgia World Congress Center, Atlanta, United States Duration: 11 Dec 2021 → 14 Dec 2021 Conference number: 63

Conference

Conference	Ash Annual Meeting & Exposition
Number	63
Location	Georgia World Congress Center
Country/Territory	United States
City	Atlanta
Period	11/12/2021 → 14/12/2021

Access to Document

10.1182/blood-2021-146161

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Eichhorst, B., Niemann, C., Kater, A. P., Fürstenau, M., Von Tresckow, J., Zhang, C., Robrecht, S., Gregor, M., Juliusson, G., Thornton, P., Staber, P. B., Tadmor, T., Lindström, V., Da Cunha-Bang, C., Schneider, C., Poulsen, C. B., Illmer, T., Schöttker, B., Janssens, A., ... Hallek, M. (2021). A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. Blood, 138(Suppl. 1), Article 71. https://doi.org/10.1182/blood-2021-146161

Eichhorst, Barbara ; Niemann, Carsten ; Kater, Arnon P. et al. / A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. In: Blood. 2021 ; Vol. 138, No. Suppl. 1.

@article{9ae1668adaa149d6a2e18f28579a69cf,

title = "A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial",

author = "Barbara Eichhorst and Carsten Niemann and Kater, {Arnon P.} and Moritz F{\"u}rstenau and {Von Tresckow}, Julia and Can Zhang and Sandra Robrecht and Michael Gregor and Gunnar Juliusson and Patrick Thornton and Staber, {Philipp B.} and Tamar Tadmor and Vesa Lindstr{\"o}m and {Da Cunha-Bang}, Caspar and Christof Schneider and Poulsen, {Christian Bj{\o}rn} and Thomas Illmer and Bj{\"o}rn Sch{\"o}ttker and Ann Janssens and Ilse Christiansen and Thomas Noesslinger and Michael Baumann and {van der Klift}, Marjolein and Ulrich Jaeger and Henrik Frederiksen and Leijs, {Maria B.L.} and Mels Hoogendoorn and Kourosh Lotfi and Holger Hebart and Tobias Gaska and Koene, {Harry R.} and Florian Simon and {De Silva}, Nisha and Anna-Maria Fink and Kirsten Fischer and Clemens-Martin Wendtner and Karl-Anton Kreuzer and Matthias Ritgen and Monika Br{\"u}ggemann and Eugen Tausch and Mark-David Levin and {Van Oers}, {Marinus H.J.} and Geisler, {Christian H.} and Stephan Stilgenbauer and Michael Hallek",

year = "2021",

month = nov,

day = "1",

doi = "10.1182/blood-2021-146161",

language = "English",

volume = "138",

journal = "Blood",

issn = "0006-4971",

publisher = "AMER SOC HEMATOLOGY",

number = "Suppl. 1",

note = "Ash Annual Meeting & Exposition, Ash 2021 ; Conference date: 11-12-2021 Through 14-12-2021",

}

Eichhorst, B, Niemann, C, Kater, AP, Fürstenau, M, Von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, PB, Tadmor, T, Lindström, V, Da Cunha-Bang, C, Schneider, C, Poulsen, CB, Illmer, T, Schöttker, B, Janssens, A, Christiansen, I, Noesslinger, T, Baumann, M, van der Klift, M, Jaeger, U, Frederiksen, H, Leijs, MBL, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, HR, Simon, F, De Silva, N, Fink, A-M, Fischer, K, Wendtner, C-M, Kreuzer, K-A, Ritgen, M, Brüggemann, M, Tausch, E, Levin, M-D, Van Oers, MHJ, Geisler, CH, Stilgenbauer, S & Hallek, M 2021, 'A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial', Blood, vol. 138, no. Suppl. 1, 71. https://doi.org/10.1182/blood-2021-146161

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. / Eichhorst, Barbara; Niemann, Carsten; Kater, Arnon P. et al.
In: Blood, Vol. 138, No. Suppl. 1, 71, 01.11.2021.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

AU - Eichhorst, Barbara

AU - Niemann, Carsten

AU - Kater, Arnon P.

AU - Fürstenau, Moritz

AU - Von Tresckow, Julia

AU - Zhang, Can

AU - Robrecht, Sandra

AU - Gregor, Michael

AU - Juliusson, Gunnar

AU - Thornton, Patrick

AU - Staber, Philipp B.

AU - Tadmor, Tamar

AU - Lindström, Vesa

AU - Da Cunha-Bang, Caspar

AU - Schneider, Christof

AU - Poulsen, Christian Bjørn

AU - Illmer, Thomas

AU - Schöttker, Björn

AU - Janssens, Ann

AU - Christiansen, Ilse

AU - Noesslinger, Thomas

AU - Baumann, Michael

AU - van der Klift, Marjolein

AU - Jaeger, Ulrich

AU - Frederiksen, Henrik

AU - Leijs, Maria B.L.

AU - Hoogendoorn, Mels

AU - Lotfi, Kourosh

AU - Hebart, Holger

AU - Gaska, Tobias

AU - Koene, Harry R.

AU - Simon, Florian

AU - De Silva, Nisha

AU - Fink, Anna-Maria

AU - Fischer, Kirsten

AU - Wendtner, Clemens-Martin

AU - Kreuzer, Karl-Anton

AU - Ritgen, Matthias

AU - Brüggemann, Monika

AU - Tausch, Eugen

AU - Levin, Mark-David

AU - Van Oers, Marinus H.J.

AU - Geisler, Christian H.

AU - Stilgenbauer, Stephan

AU - Hallek, Michael

N1 - Conference code: 63

PY - 2021/11/1

Y1 - 2021/11/1

U2 - 10.1182/blood-2021-146161

DO - 10.1182/blood-2021-146161

M3 - Conference abstract in journal

SN - 0006-4971

VL - 138

JO - Blood

JF - Blood

IS - Suppl. 1

M1 - 71

T2 - Ash Annual Meeting & Exposition

Y2 - 11 December 2021 through 14 December 2021

ER -

Eichhorst B, Niemann C, Kater AP, Fürstenau M, Von Tresckow J, Zhang C et al. A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. Blood. 2021 Nov 1;138(Suppl. 1):71. doi: 10.1182/blood-2021-146161